Significant events related to the medical diagnostics company, Quest Diagnostics (DGX), have recently been reported. Their shares were promoted to a buy rating, while Braun Stacey Associates Inc and Boston Trust Walden Corp made strategic moves regarding ownership of DGX shares. The company also declared a quarterly cash dividend and experienced a surge in Fentanyl positivity in 2025. The firm also solidified a key joint venture deal with Corewell Health to expand laboratory services in Michigan. Quest Diagnostics reported both Q2 and Q3 2025 earnings, exceeding expectations and resulting in a raised outlook, which could potentially impact the healthcare sector's performance. Further highlights of their Q3 financial results included the introduction of Oropouche Virus testing, advances in Pharmacogenomics, and the strong competition against slower-growth narratives. Looking forward, Quest Diagnostics will be speaking at major healthcare conferences and has launched a new blood test to aid the diagnosis of Alzheimer's Disease. Lastly, collaborations with Google Cloud and WHOOP aim to elevate data handling and customer experience in diagnostic testing.
Quest Diagnostics DGX News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sat, 03 Jan 2026 13:04:15 GMT -
Rating 8
- Innovation 7
- Rumor 6
